<DOC>
	<DOCNO>NCT01130077</DOCNO>
	<brief_summary>The overall objective pilot study collect immunological safety data follow administration vaccination HLA-A2 . This data use decide whether large study clinical efficacy warrant .</brief_summary>
	<brief_title>A Pilot Study Glioma Associated Antigen Vaccines Conjunction With Poly-ICLC Pediatric Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>**Inclusion Criteria *Tumor Types Tumor type/location : Stratum A : Newly diagnose diffuse intrinsic pontine glioma OR biopsy proven highgrade glioma* involve brainstem . Patients may receive chemotherapy radiation . ( Note : Stratum A closed accrual . ) Stratum B : Newly diagnose , nonbrainstem highgrade glioma* Patients may receive chemotherapy radiation . ( Note : Stratum B open accrual . ) Stratum C : Unresectable lowgrade glioma receive least two chemotherapy/biologic regimen . Patients may receive radiation index lesion within 1 year enrollment . ( Note : Stratum C close accrual . ) Stratum D : Nonbrainstem highgrade gliomas* recur follow treatment . ( Note : Stratum D close accrual . ) Stratum E : Newly diagnose highgrade gliomas* brain stem gliomas receive chemotherapy radiation therapy . Patients may receive chemotherapy radiation therapy complete . ( Note : Stratum E close accrual . ) Stratum F : Newly diagnose highgrade glioma metastatic disease within CNS require craniospinal radiation therapy . Patients may may receive chemotherapy radiation , receive chemotherapy radiation therapy complete . ( Note : Stratum F close accrual . ) Eligible histology include glioblastoma ( GBM ) , anaplastic astrocytoma ( AA ) gliosarcoma . Patients oligodendroglioma component NOT eligible . HLAA2 positive base flow cytometry . Patients Stratum A B E must receive standard involved field radiation therapy [ RT ] define fractionated external beam radiotherapy total dose 50006000 cGy . Patients strata must register within 412 week complete RT . Patients Stratum F must receive craniospinal radiation . Patients must clinically stable lowdose ( 0.1 mg/kg/day , max 4 mg/day Dexamethasone ) corticosteroid least one week prior study registration . All patient must sign IRBapproved informed consent document Patients must ≥ 12 month &lt; 22 year age time study registration . Patients must performance status ≥ 60 . Patients must life expectancy least 8 week . Documented negative serum βHCG female patient postmenarchal . Pregnant female include study . Males females must agree use effective birth control method course vaccination . Patients must free systemic infection . Patients adequate organ function measure : Bone marrow : ANC &gt; 1,000/µl ; Platelets &gt; 100,000/µl ( transfusion independent ) ; absolute lymphocyte count ≥500/uL ; Hemoglobin &gt; 8 g/dl ( may transfuse ) . Hepatic : bilirubin ≤ 1.5x institutional normal age ; SGPT ( ALT ) &lt; 3x institutional normal . Renal : Serum creatinine base age Creatinine clearance radioisotope GFR &gt; 70 ml/min/ml/min/1.73 m² Patients Strata C D must recover toxic effect prior therapy : least 3 week form last dose standard cytotoxic chemotherapy myelosuppressive biological therapy least 1 week last dose nonmyelosuppressive biologic therapy . No overt cardiac , gastrointestinal , pulmonary psychiatric disease . Patients live outside North America eligible . Presence metastatic disease patient Stratum A , B , D E. Patients low grade glioma ( stratum C ) may tumor spread within CNS . Patients Stratum F must tumor spread within CNS . Patients enrol Strata A B may receive prior chemotherapy antiglioma therapy type radiation therapy . Patients enrol stratum C must receive least two prior chemotherapy biologic therapy regimens may receive radiation index lesion within 1 year enrollment . Patients Strata A , B , E , F receive chemotherapy radiation therapy complete . Concurrent treatment medication ( must least 1 week ) include : Interferon ( e.g . IntronA® ) Allergy desensitization injection Growth factor ( e.g . Procrit® , Aranesp® , Neulasta® ) Interleukins ( e.g . Proleukin® ) Any investigational therapeutic medication Patients must history , currently active autoimmune disorder . Use immunosuppressives within four week prior study entry . Dexamethasone , corticosteroid medication , use perioperative period and/or radiotherapy , must taper ( 0.1 mg/kg/day , max 4 mg/day dexamethasone ) least one week study registration . Topical corticosteroid acceptable . Patients know addiction alcohol illicit drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric glioma</keyword>
	<keyword>Vaccine therapy</keyword>
</DOC>